Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glumetinib versus docetaxel in previously treated MET-overexpressing driver-negative advanced NSCLC
jRCT2031240494Phase 3Active, not recruiting
- Sponsor
- Haihe
- Start
- May 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in non-small cell lung cancer (NSCLC) comparing Glumetinib with Docetaxel (2 arms). Primary endpoint: Overall survival. Started May 2025; status: active, not recruiting.
02
Drugs
glumetinibdocetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031240494.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240494.